Subscribe to RSS
Please copy the URL and add it into your RSS Feed Reader.
https://www.thieme-connect.de/rss/thieme/en/10.1055-s-00000071.xml
Download PDF
Semin Neurol 2025; 45(02): 198-205
DOI: 10.1055/a-2551-0688
DOI: 10.1055/a-2551-0688
Review Article
Special Issues in Medical Management: Hormones and Pregnancy in Epilepsy
Funding U.S. Department of Health and Human Services > National Institutes of Health K23AG063899.
Abstract
The relationship between sex hormones and epilepsy involves intricate interactions that influence seizure susceptibility, reproductive health, and treatment approaches. Estrogen generally exhibits proconvulsant effects, while progesterone and its metabolite allopregnanolone have anticonvulsant properties. Variability in hormone levels during the menstrual cycle can exacerbate seizures, a phenomenon known as catamenial epilepsy. Effective management often requires a tailored combination of antiseizure medications (ASMs) and hormonal therapies. Women and others of childbearing potential face unique challenges, including higher rates of menstrual dysfunction, potential exacerbation of seizures during pregnancy, and increased risks associated with hormonal contraception and menopause. Careful ASM selection is critical to ensure maternal and fetal safety, with lamotrigine, levetiracetam, and oxcarbazepine being preferred options. Postpartum ASM adjustments and breastfeeding considerations are also essential for optimizing outcomes. Emerging research highlights the impact of hormonal interactions in transgender individuals undergoing gender-affirming therapies. For transwomen, estrogen could heighten seizure risk. Close monitoring and collaboration between health care providers are crucial for personalized care. The complex interplay between hormones and epilepsy underscores the need for ongoing research and individualized approaches to optimize seizure control and address the unique reproductive health needs of people with epilepsy.
Keywords
epilepsy - women with epilepsy - catamenial epilepsy - hormones - contraception - pregnancy - menopause - LGBT - transgenderPublication History
Article published online:
03 April 2025
© 2025. Thieme. All rights reserved.
Thieme Medical Publishers, Inc.
333 Seventh Avenue, 18th Floor, New York, NY 10001, USA
-
References
- 1 Catenaccio E, Mu W, Lipton ML. Estrogen- and progesterone-mediated structural neuroplasticity in women: evidence from neuroimaging. Brain Struct Funct 2016; 221 (08) 3845-3867
- 2 Velísková J, De Jesus G, Kaur R, Velísek L. Females, their estrogens, and seizures. Epilepsia 2010; 51 Suppl 3 (Suppl. 03) 141-144
- 3 Taubøll E, Sveberg L, Svalheim S. Interactions between hormones and epilepsy. Seizure 2015; 28: 3-11
- 4 Logothetis J, Harner R, Morrell F, Torres F. The role of estrogens in catamenial exacerbation of epilepsy. Neurology 1959; 9 (05) 352-360
- 5 Scharfman HE, MacLusky NJ. The influence of gonadal hormones on neuronal excitability, seizures, and epilepsy in the female. Epilepsia 2006; 47 (09) 1423-1440
- 6 Guennoun R. Progesterone in the brain: Hormone, neurosteroid and neuroprotectant. Int J Mol Sci 2020; 21 (15) 5271
- 7 Herzog AG. Hormonal therapies: progesterone. Neurotherapeutics 2009; 6 (02) 383-391
- 8 Lonsdale D, Nylen K, McIntyre Burnham W. The anticonvulsant effects of progesterone and its metabolites on amygdala-kindled seizures in male rats. Brain Res 2006; 1101 (01) 110-116
- 9 Rhodes ME, Frye CA. Progestins in the hippocampus of female rats have antiseizure effects in a pentylenetetrazole seizure model. Epilepsia 2004; 45 (12) 1531-1538
- 10 Mohammad S, Abolhassan A, Pourgholami MH. Evaluation of the anticonvulsant profile of progesterone in male amygdala-kindled rats. Epilepsy Res 1998; 30 (03) 195-202
- 11 Reddy DS, Gangisetty O, Briyal S. Disease-modifying activity of progesterone in the hippocampus kindling model of epileptogenesis. Neuropharmacology 2010; 59 (7–8): 573-581
- 12 Bäckström T, Zetterlund B, Blom S, Romano M. Effects of intravenous progesterone infusions on the epileptic discharge frequency in women with partial epilepsy. Acta Neurol Scand 1984; 69 (04) 240-248
- 13 Reddy DS, Castaneda DC, O'Malley BW, Rogawski MA. Anticonvulsant activity of progesterone and neurosteroids in progesterone receptor knockout mice. J Pharmacol Exp Ther 2004; 310 (01) 230-239
- 14 Vaitkevicius H, Husain AM, Rosenthal ES. et al. First-in-man allopregnanolone use in super-refractory status epilepticus. Ann Clin Transl Neurol 2017; 4 (06) 411-414
- 15 Broomall E, Natale JE, Grimason M. et al. Pediatric super-refractory status epilepticus treated with allopregnanolone. Ann Neurol 2014; 76 (06) 911-915
- 16 Vasquez A, Farias-Moeller R, Tatum W. Pediatric refractory and super-refractory status epilepticus. Seizure 2019; 68: 62-71
- 17 Reddy DS, Mbilinyi RH, Estes E. Preclinical and clinical pharmacology of brexanolone (allopregnanolone) for postpartum depression: a landmark journey from concept to clinic in neurosteroid replacement therapy. Psychopharmacology (Berl) 2023; 240 (09) 1841-1863
- 18 Knight EMP, Amin S, Bahi-Buisson N. et al.; Marigold Trial Group. Safety and efficacy of ganaxolone in patients with CDKL5 deficiency disorder: results from the double-blind phase of a randomised, placebo-controlled, phase 3 trial. Lancet Neurol 2022; 21 (05) 417-427
- 19 Meng J, Yan Z, Tao X. et al. The efficacy and safety of ganaxolone for the treatment of refractory epilepsy: A meta-analysis from randomized controlled trials. Epilepsia Open 2023; 8 (01) 90-99
- 20 Herzog AG, Mandle HB, MacEachern DB. Does the age of seizure onset relate to menarche and does it matter?. Seizure 2019; 69: 1-6
- 21 Herzog AG, Friedman MN. Menstrual cycle interval and ovulation in women with localization-related epilepsy. Neurology 2001; 57 (11) 2133-2135
- 22 Klein P, van Passel-Clark LMA, Pezzullo JC. Onset of epilepsy at the time of menarche. Neurology 2003; 60 (03) 495-497
- 23 Harden CL, Koppel BS, Herzog AG, Nikolov BG, Hauser WA. Seizure frequency is associated with age at menopause in women with epilepsy. Neurology 2003; 61 (04) 451-455
- 24 Harden CL. Polycystic ovaries and polycystic ovary syndrome in epilepsy: evidence for neurogonadal disease. Epilepsy Curr 2005; 5 (04) 142-146
- 25 Joffe H, Hayes FJ. Menstrual cycle dysfunction associated with neurologic and psychiatric disorders: their treatment in adolescents. Ann N Y Acad Sci 2008; 1135: 219-229
- 26 Bilo L, Meo R, Valentino R, Buscaino GA, Striano S, Nappi C. Abnormal pattern of luteinizing hormone pulsatility in women with epilepsy. Fertil Steril 1991; 55 (04) 705-711
- 27 Herzog AG. Polycystic ovarian syndrome in women with epilepsy: epileptic or iatrogenic?. Ann Neurol 1996; 39 (05) 559-560
- 28 Herzog AG, Klein P, Ransil BJ. Three patterns of catamenial epilepsy. Epilepsia 1997; 38 (10) 1082-1088
- 29 Herzog AG, Harden CL, Liporace J. et al. Frequency of catamenial seizure exacerbation in women with localization-related epilepsy. Ann Neurol 2004; 56 (03) 431-434
- 30 Herzog AG, Fowler KM, Smithson SD. et al.; Progesterone Trial Study Group. Progesterone vs placebo therapy for women with epilepsy: A randomized clinical trial. Neurology 2012; 78 (24) 1959-1966
- 31 Gerard EE, Meador KJ. Managing epilepsy in women. Continuum (Minneap Minn) 2016; 22 (1 Epilepsy): 204-226
- 32 Harden CL, Pulver MC, Ravdin L, Jacobs AR. The effect of menopause and perimenopause on the course of epilepsy. Epilepsia 1999; 40 (10) 1402-1407
- 33 Abbasi F, Krumholz A, Kittner SJ, Langenberg P. Effects of menopause on seizures in women with epilepsy. Epilepsia 1999; 40 (02) 205-210
- 34 Harden CL, Herzog AG, Nikolov BG. et al. Hormone replacement therapy in women with epilepsy: a randomized, double-blind, placebo-controlled study. Epilepsia 2006; 47 (09) 1447-1451
- 35 Peebles CT, McAuley JW, Moore JL, Malone HJ, Reeves AL. Hormone replacement therapy in a postmenopausal woman with epilepsy. Ann Pharmacother 2000; 34 (09) 1028-1031
- 36 Davis SR, Pinkerton J, Santoro N, Simoncini T. Menopause-Biology, consequences, supportive care, and therapeutic options. Cell 2023; 186 (19) 4038-4058
- 37 Johnson EL. Contraception for women with epilepsy. Curr Obstet Gynecol Rep 2018; 7: 146-152
- 38 Reimers A, Helde G, Brodtkorb E. Ethinyl estradiol, not progestogens, reduces lamotrigine serum concentrations. Epilepsia 2005; 46 (09) 1414-1417
- 39 McGrath A, Sharpe L, Lah S, Parratt K. Pregnancy-related knowledge and information needs of women with epilepsy: a systematic review. Epilepsy Behav 2014; 31: 246-255
- 40 Bjørk M, Riedel B, Spigset O. et al. Association of folic acid supplementation during pregnancy with the risk of autistic traits in children exposed to antiepileptic drugs in utero. JAMA Neurol 2018; 75 (02) 160-168
- 41 Pack AM, Oskoui M, Williams Roberson S. et al. Teratogenesis, perinatal, and neurodevelopmental outcomes after in utero exposure to antiseizure medication: Practice guideline from the AAN, AES, and SMFM. Neurology 2024; 102 (11) e209279
- 42 Abe K, Hamada H, Yamada T, Obata-Yasuoka M, Minakami H, Yoshikawa H. Impact of planning of pregnancy in women with epilepsy on seizure control during pregnancy and on maternal and neonatal outcomes. Seizure 2014; 23 (02) 112-116
- 43 Samsonsen C, Karanauskaitė U, Stenbacka EJ, Hjelvik ES, Rektorli L, Brodtkorb E. Pregnancy planning in women with epilepsy: A single center observational study with focus on epilepsy type. Seizure 2024; 123: 152-158
- 44 Herzog AG, Mandle HB, Cahill KE, Fowler KM, Hauser WA. Predictors of unintended pregnancy in women with epilepsy. Neurology 2017; 88 (08) 728-733
- 45 Johnson EL, Burke AE, Wang A, Pennell PB. Unintended pregnancy, prenatal care, newborn outcomes, and breastfeeding in women with epilepsy. Neurology 2018; 91 (11) e1031-e1039
- 46 Vajda FJE, O'Brien TJ, Graham JE, Hitchcock AA, Lander CM, Eadie MJ. Predicting epileptic seizure control during pregnancy. Epilepsy Behav 2018; 78: 91-95
- 47 Pennell PB, French JA, May RC. et al.; MONEAD Study Group. Changes in seizure frequency and antiepileptic therapy during pregnancy. N Engl J Med 2020; 383 (26) 2547-2556
- 48 Pennell PB, Peng L, Newport DJ. et al. Lamotrigine in pregnancy: clearance, therapeutic drug monitoring, and seizure frequency. Neurology 2008; 70 (22 Pt 2): 2130-2136
- 49 Brodtkorb E, Reimers A. Seizure control and pharmacokinetics of antiepileptic drugs in pregnant women with epilepsy. Seizure 2008; 17 (02) 160-165
- 50 Edey S, Moran N, Nashef L. SUDEP and epilepsy-related mortality in pregnancy. Epilepsia 2014; 55 (07) e72-e74
- 51 Veiby G, Bjørk M, Engelsen BA, Gilhus NE. Epilepsy and recommendations for breastfeeding. Seizure 2015; 28: 57-65
- 52 Birnbaum AK, Meador KJ, Karanam A. et al.; MONEAD Investigator Group. Antiepileptic drug exposure in infants of breastfeeding mothers with epilepsy. JAMA Neurol 2020; 77 (04) 441-450
- 53 Meador KJ, Baker GA, Browning N. et al.; Neurodevelopmental Effects of Antiepileptic Drugs (NEAD) Study Group. Breastfeeding in children of women taking antiepileptic drugs: cognitive outcomes at age 6 years. JAMA Pediatr 2014; 168 (08) 729-736
- 54 Artama M, Isojärvi JIT, Auvinen A. Antiepileptic drug use and birth rate in patients with epilepsy–a population-based cohort study in Finland. Hum Reprod 2006; 21 (09) 2290-2295
- 55 Pennell PB, French JA, Harden CL. et al. Fertility and birth outcomes in women with epilepsy seeking pregnancy. JAMA Neurol 2018; 75 (08) 962-969
- 56 Moores G, Liu K, Pikula A, Bui E. Fertility treatment for people with epilepsy. Pract Neurol 2024; 24 (04) 296-301
- 57 Mostacci B, Esposto R, Lello S, Bisulli F, Licchetta L, Tinuper P. Estrogen-related seizure exacerbation following hormone therapy for assisted reproduction in women with epilepsy. Seizure 2018; 61: 200-202
- 58 Abdulrazaq AA, Ainsworth AJ, Britton JW. et al. Seizure control in women with epilepsy undergoing assisted reproductive technology. Epilepsia 2023; 64 (10) e207-e213
- 59 Johnson EL, Bui E, Tassiopoulos K. et al. Prevalence of epilepsy in people of sexual and gender minoritized groups. JAMA Neurol 2024; 81 (09) 996-999
- 60 Tangpricha V, den Heijer M. Oestrogen and anti-androgen therapy for transgender women. Lancet Diabetes Endocrinol 2017; 5 (04) 291-300
- 61 Teyler TJ, Vardaris RM, Lewis D, Rawitch AB. Gonadal steroids: effects on excitability of hippocampal pyramidal cells. Science 1980; 209 (4460): 1017-1018
- 62 Saberi M, Pourgholami MH, Jorjani M. The acute effects of estradiol benzoate on amygdala-kindled seizures in male rats. Brain Res 2001; 891 (1-2): 1-6
- 63 Waldman G, Benson R. Epilepsy care in transgender patients. Curr Neurol Neurosci Rep 2022; 22 (08) 451-458
- 64 Johnson EL, Kaplan PW. Caring for transgender patients with epilepsy. Epilepsia 2017; 58 (10) 1667-1672
- 65 D'hoore L, T'Sjoen G. Gender-affirming hormone therapy: An updated literature review with an eye on the future. J Intern Med 2022; 291 (05) 574-592